On March 9, 2016, Li, Yao; Wei, Yonggang; Zhang, Guobiao; Chen, Lei; Zhang, Xiaobo; Qiu, Guanpeng; Xu, Bo published a patent.HPLC of Formula: 16230-24-3 The title of the patent was Pyrimidine derivative, its preparation method and pharmaceutical application. And the patent contained the following:
The invention disclosed a kind of pyrimidine derivative, its preparation method and pharmaceutical application. The claimed pyrimidine derivative i shown in structure I (M1,M2 = (un)substituted Michael receptor groups; ring D = 6-10 member heterocycle, ring E,A = C6-10 ring, or 4-10 member heterocycle, etc.; ring B,C = (un)substituted 4-7 heterocycle, or not exist; W1,W2 = Nh, O or S; W3,W4 = NH, O, S or not exist). The claimed compound is prepared via multiple steps (procedure given). The obtained compound, its stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt, eutectic, or prodrug, can be used as EGFR inhibitor for treating or prevention hyperproliferative diseases such as brain tumors, non-small cell lung cancer, squamous cell cancer, bladder cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, colorectal cancer, renal cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, solid tumors, Non-Hodgkin’s lymphoma, liver cancer, lung cancer, skin cancer, thyroid cancer, head and neck cancer, prostate cancer, glioma and nasopharyngeal carcinoma. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).HPLC of Formula: 16230-24-3
The Article related to pyrimidine derivative preparation egfr inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.HPLC of Formula: 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics